代表论文 (*通讯作者)：

1. Ma J, He Q, Pu J, Liu Y, Cui X, Wang G, Chen Q, Ren L, Li M, Hou P*. SNORD50A/B disassemble ASC-1 complex to silence NF-κB and boost PD-1 blockade in non-small-cell lung cancer. NPJ Precis Oncol. 2026 May 25. (IF: 9.9, Q1）

2. Zhang R, Zong D, Liu R, Wang Y, Gu Q, Yao Y, Zheng W, Yuan M, Wang S, Cui R, Li D, Dang S, Hou P*. TRMT6-Mediated m1A Modification of CDK9 mRNA Is a Dual-Pronged Pathogenic Driver for HBV-Related Hepatocellular Carcinoma. Adv Sci. 2026. (IF: 14.1, Q1)

3. Dang H, Liu Y, Zhou Y, Sui M, Wang Y, Qiang W, Sui F, Zhang Y, Cao H, Wu X*, Ji M*, Hou P*. TET1 loss propels the development of hyperthyroidism by remodeling histone modifications of PAX8 promoter. Exp Mol Med. 2025 Oct;57(10):2376-2392. (IF: 17.5, Q1)

4. Gong L, Li S, Sun J, Liu R, Wang J, Wang S, Zhao Y, Yan L, Ji M, Yang D, Hou P*, Liu D*. Targeted degradation of hexokinase 2 by a novel engineered bispecific chimeric liposome-based Nano-PROTACs for enhancing tumor chemotherapy. Biomaterials. 2026 Mar;326:123651. (IF: 13.6, Q1）

5. Wei J, Liu J, Zhang Y, Wang G, Cui X, Yu W*, Nie C*, Hou P*. Blocking interplay between TERT and c-Myc: a new therapeutic strategy for BRAFV600E/pTERT double mutated tumors. Int J Biol Sci. 2025 Jul 28;21(11):4961-4978. (IF: 11.7, Q1）

6. Zhang H, Zeng Z, Liu Y, Zheng W, Wang J, Yao Y, Wang Y, Ji M*, Hou P*. Thyrotropin exacerbates insulin resistance by triggering macrophage inflammation in subclinical hypothyroidism. Exp Mol Med. 2025. (IF: 17.5, Q1)

7. Liu Z, Li Y, Wang S, Wang Y, Sui M, Liu J, Chen P, Wang J, Zhang Y, Dang C, Hou P*. Genome-wide CRISPR screening identifies PHF8 as an effective therapeutic target for KRAS- or BRAF-mutant colorectal cancers. J Exp Clin Cancer Res. 2025 Feb 25;44(1):70. (IF: 14.3, Q1)

8. Yuan M, Shi L, Liu Y, Xiang K, Zhang Y, Zhou Y, Wang J, Ji M, Hou P*. Disulfiram/copper triggers cGAS-STING innate immunity pathway via ROS-induced DNA damage that potentiates antitumor response to PD-1 checkpoint blockade. Int J Biol Sci. 2025 Feb 3;21(4):1730-1748. (IF: 11.7, Q1)

9. Liu Y, Yuan M, Xu X, Yang H, Yao Y, Hou P*, Yu W*, Ji M*. USP44 inactivation accelerates the progression of thyroid cancer by inducing ubiquitylation and degradation of p21. Int J Biol Sci.  2024 23;20(13):5223-5238. (IF: 11.7, Q1)

10. Zhou Y, Wang S, Guo J, Li C, Sui M, Zeng Z, Dang H, Gu Q, Zhu J*, Cheng Y*, Hou P*. Harnessing transcription factor-driven ROS for synergistic multimodal lung cancer treatment. J Control Release. 2024; 374:489-504. (IF: 12.4, Q1)

11. Zhang R, Chen P, Wang Y, Zeng Z, Yang H, Li M, Liu X*, Yu W*, Hou P*. Targeting METTL3 enhances the chemosensitivity of non-small cell lung cancer cells by decreasing ABCC2 expression in an m(6)A-YTHDF1-dependent manner. Int J Biol Sci. 2024; 20(12):4750-66. (IF: 11.7, Q1)

12. Ren X, Feng C, Wang Y, Chen P, Wang S, Wang J, Cao H, Li Y, Ji M*, Hou P*. SLC39A10 promotes malignant phenotypes of gastric cancer cells by activating the CK2-mediated MAPK/ERK and PI3K/AKT pathways. Exp Mol Med. 2023;55(8):1757-1769. (IF: 17.5, Q1)

13. Yang Q, Dang H, Liu J, Wang X, Wang J, Lan X, Ji M*, Xing M*, Hou P*. Hypoxia switches TET1 from being tumor-suppressive to oncogenic. Oncogene. 2023;42(20):1634-8. (IF: 9.1, Q1)

14. Zeng Z, Zheng W, Hou P*. The role of drug-metabolizing enzymes in synthetic lethality of cancer. Pharmacol Ther. 2022;240:108219. (IF: 13.5, Q1)

15. Ma S, Wang N, Liu R, Zhang R, Dang H, Wang Y, Wang S, Zeng Z, Ji M*, Hou P*. ZIP10 is a negative determinant for anti-tumor effect of mannose in thyroid cancer by activating phosphate mannose isomerase. J Exp Clin Cancer Res. 2021;40(1):387. (IF: 14.3, Q1)

16. Da C, Pu J, Liu Z, Wei J, Qu Y, Wu Y, Shi B, Yang J*, He N*, Hou P*. HACE1-mediated NRF2 activation causes enhanced malignant phenotypes and decreased radiosensitivity of glioma cells. Signal Transduct Target Ther. 2021;6(1):399. (IF: 81.2, Q1)

17. Su X, Feng C, Wang S, Shi L, Gu Q, Zhang H, Lan X, Zhao Y, Qiang W, Ji M*, Hou P*. The noncoding RNAs SNORD50A and SNORD50B-mediated TRIM21-GMPS interaction promotes the growth of p53 wild-type breast cancers by degrading p53. Cell Death Differ. 2021;28(8):2450-2464. (IF: 13.6, Q1)

18. Wang S, Zhou X, Zeng Z, Sui M, Chen L, Feng C, Huang C, Yang Q, Ji M, Hou P*. Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by improving hypoxic tumor microenvironment. J Nanobiotechnology. 2021;19(1):302. (IF: 15.0, Q1)

19. Li Y, Su X, Feng C, Liu S, Guan H, Sun Y, He N*, Ji M*, Hou P*. CYP2S1 is a synthetic lethal target in BRAF V600E-driven thyroid cancers. Signal Transduct Target Ther. 2020;5(1):191. ( IF: 81.2, Q1)

20. He W, Yan J, Li Y, Yan S, Wang S, Hou P*, Lu W*. Resurrecting a p53 peptide activator - An enabling nanoengineering strategy for peptide therapeutics. J Control Release. 2020;325:293-303. (IF: 12.4, Q1)

21. Li M, Ruan B, Wei J, Yang Q, Chen M, Ji M*, Hou P*. ACYP2 contributes to malignant progression of glioma through promoting Ca²⁺ efflux and subsequently activating c-Myc and STAT3 signals. J Exp Clin Cancer Res. 2020;39(1):106. (IF: 14.3, Q1)

22. Su X, Shen Z, Yang Q, Sui F, Pu J, Ma J, Ma S, Yao D, Ji M*, Hou P*. Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK/ERK and PI3K/AKT pathways via distinct mechanisms. Theranostics. 2019;9(15):4461-4473. (IF: 14.9, Q1)

23. Yang Q, Jiang W, Hou P*. Emerging role of PI3K/AKT in tumor-related epigenetic regulation. Semin Cancer Biol. 2019;59:112-124. (IF: 20.3, Q1)

24. He W, Yan J, Wang L, Lei B, Hou P*, Lu W*, Ma PX*. A lanthanide-peptide-derived bacterium-like nanotheranostic with high tumor-targeting, -imaging and -killing properties. Biomaterials. 2019;206:13-24. (IF: 13.6, Q1)

25. He W, Wang S, Yan J, Qu Y, Jin L, Sui F, Li Y, You W, Yang G, Yang Q, Ji M, Liu M, Shao Y, Ma PX*, Lu W*, Hou P*. Self-assembly of therapeutic peptide into stimuli-responsive clustered nanohybrids for cancer-targeted therapy. Adv Funct Mater. 2019;29(10):1807736. (IF: 19.9, Q1)

26. Dang S, Zhou J, Chen Y, Chen P, Ji M, Shi B, Yang Q*, Hou P*. Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis. Oncogene. 2019;38(24):4804-4819. (IF: 9.1, Q1)

27. Bian Z, Yan J, Wang S, Li Y, Guo Y, Ma B, Guo H, Lei Z, Yin C, Zhou Y, Liu M, Tao K*, Hou P*, He W*. Awakening p53 in vivo by D-peptides-functionalized ultra-small nanoparticles: Overcoming biological barriers to D-peptide drug delivery. Theranostics. 2018;8(19):5320-5335. (IF: 14.9, Q1)

28. Li H, Tian Z, Qu Y, Yang Q, Guan H, Shi B, Ji M*, Hou P*. SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via DBC1/SIRT1 axis. Oncogene. 2019;38(3):345-359. (IF: 9.1, Q1)

29. He W*, Yan J, Sui F, Wang S, Su X, Qu Y, Yang Q, Guo H, Ji M, Lu W, Shao Y*, Hou P*. Turning a Luffa protein into a self-assembled biodegradable nanoplatform for multitargeted cancer therapy. ACS Nano. 2018;12(11):11664-11677. (IF: 17.3, Q1)

30. Li Y, Yang Q, Guan H, Shi B, Ji M, Hou P*. ZNF677 is a potent tumor suppressor in thyroid cancer through inhibiting Akt phosphorylation. Cancer Res. 2018;78(18):5216-5228. (IF: 22.6, Q1)

31. Qu Y, Shi B, Hou P*. Activated ERK: An emerging player in miRNA downregulation. Trends in Cancer. 2017;3(3):163-165. (IF: 21.6, Q1)

32. Qu Y, Yang Q, Liu J, Shi B, Ji M, Li G, Hou P*. c-Myc is required for BRAFV600E-induced epigenetic silencing by H3K27me3 in tumorigenesis. Theranostics. 2017; 7(8):2092-2107. (IF: 14.9, Q1)

33. Yang Q and Hou P*. Targeting PFKFB3 in the endothelium for cancer therapy. Trends Mol Med. 2017;23(3):197-200. (IF: 18.1, Q1)

34. Hou P, Liu D, Shan Y, Hu S, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007;13(4):1161-70.(IF: 10.9, Q1) 

35. Hou P, Liu D, Xing M*. The T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene. Leukemia. 2007;21(10):2216-8. (IF: 8.8, Q1)

36. Hou P*, Chen Z, Ji M, He N, Lu Z*. Real-time PCR assay for ultrasensitive quantification of DNA-binding proteins. Clin Chem. 2007;53(4):581-6. (IF: 8.3, Q1)

37. Hou P, Ji M, Li S, Lu Z*. Microarray-based approach for high-throughput genotyping of single-nucleotide polymorphisms with layer-by-layer dual-color fluorescence hybridization. Clin Chem. 2004;50(10):1955-7. (IF: 8.3, Q1)

38. Hou P, Ji M, Ge C, Shen J, Li S, He N, Lu Z*. Detection of methylation of human p16(Ink4a) gene 5'-CpG islands by electrochemical method coupled with linker-PCR. Nucleic Acids Res. 2003;31(16):e92. (IF: 15.0, Q1)

      其它SCI论文请链接http://www.ncbi.nlm.nih.gov/pubmed/?term=peng+hou